• Contact us: 01476 247 007
    Advice for Management of Clinical trials in relation to CoronavirusAdvice for Management of Clinical trials in relation to CoronavirusAdvice for Management of Clinical trials in relation to CoronavirusAdvice for Management of Clinical trials in relation to Coronavirus
    • How can we help
      • Pharmacovigilance
        • National contact person for pharmacovigilance – post Brexit
        • Pharmacovigilance Standard Operating Procedure Audits
        • Post Marketing Pharmacovigilance Support
        • Clinical Trial Pharmacovigilance Support
        • EU QPPV Provision
        • Quality & Compliance
        • Risk Assessment and Management
        • Signal Detection and Management
      • Medical Writing
      • Patient Information
      • Regulatory
      • Market Authorisation Holding
    • Brexit
    • Our Partners
      • Marti Farm
      • Affiliates
      • Medilink
      • External Team
    • News
    • Get in touch
    NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    17th February 2020
    It's business as usual at PDS during the coronavirus / COVID-19 crisis
    Coronavirus / COVID-19 – business as usual at PDS
    13th March 2020

    Advice for Management of Clinical trials in relation to Coronavirus

    13th March 2020
    Advice for Management of Clinical trials in relation to Coronavirus

    Advice for Management of Clinical trials in relation to CoronavirusAs we are all now terribly aware, COVID-19 is proving to be a challenge across all areas of industry.

    Recently, the MHRA have announced on their blog, that they recognise the difficulties this creates for managing trials and they would like to offer some advice.

    Please click HERE to read their advice in full.

     

     

    Share

    Related posts

    21st July 2021

    The clock is ticking! Have you appointed your National Contact Person for Pharmacovigilance yet?


    Read more
    GCP Inspections: Expectations and the dos and don’ts for hosting
    19th March 2020

    GCP Inspections: Expectations and the dos and don’ts for hosting


    Read more
    NICE agrees to look again at Novartis’ Aimovig for migraine prevention
    17th February 2020

    Good news for severe migraine suffers everywhere as NICE agrees to look again at Novartis’ Aimovig for migraine prevention


    Read more

    PLEASE NOTE OUR NEW PHONE NUMBER AS OF 1st JUNE 2021
    Call our team +44(0) 1476 247 007
    email info@puredrugsafety.com



    Sign up for our newsletter

    Pure Drug Safety Ltd

    Pure Drug Safety Ltd · 1 year ago
    @PureDrugSafety



    Many clients have already put their NCPP in place with us here at PDS and are ready for January 2022.

    Read more 👉 https://t.co/6mnM9Dzoma

    #NationalContactPerson #KnowledgeablePerson #ExperiencedQppv https://t.co/rS2W4PZbDv

    View on Twitter


    0

    0

    © 2019 - 2023 Pure Drug Safety.
    As of 1st June 2021 NEW OFFICE & REGISTERED ADDRESS: BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF, UK
    Pure Drug Safety Limited is a company registered in England and Wales. Registered Company Number 7702236. VAT Registered Number 117 966 288
    For our GDPR and Privacy Policy click here
    Designed by Gather Creative | Content managed by Tailored Marketing Solutions | Built + Hosted by GIGER MEDIA